Table 2.

Multivariate Analysis of the Associations Between the Presence of Pretreatment Major Resistance Mutations and Death Within the Cohort

	OR Model 1 (95% CI)	p value	ORs Model 2 (95% CI)	p value	ORs Model 3 (95% CI)	p value	ORs Model 4 (95% CI)	p value
Pretreatment major resistance mutations	2.55 (1.20, 5.42)	0.015	2.16 (0.98, 4.76)	0.055	1.95 (0.86, 4.42)	0.107	1.29 (0.54, 3.12)	0.566
Age in months at treatment initiation	—	—	0.95 (0.88, 1.03)	0.198	0.98 (0.90, 1.05)	0.504	0.94 (0.87, 1.02)	0.136
Pretreatment HIV-1 plasma RNA (copies/ml) ≥750K	—	—	—	—	8.46 (1.94, 36.9)	0.004	5.75 (1.26, 26.2)	0.024
Pretreatment CD4+ cell count (cells/μl) <500							2.99 (1.28, 6.99)	0.011
Pretreatment weight For age z-score							0.716 (0.55, 0.93)	0.012

Model 1 is unadjusted; Model 2 is adjusted for age at time of treatment initiation; Model 3 is adjusted for age and pretreatment plasma HIV-1 RNA level; and Model 4 is adjusted for age, pretreatment plasma HIV-1 RNA level, pretreatment CD4⁺ cell count, and pretreatment weight-for-age z-score. OR, odds ratio; K=1000.